

CLAIMS

1. Cosmetic process for treating visible and/or tactile skin irregularities, comprising the steps consisting
5 in:

(a) topically applying to the skin a composition containing, in a physiologically acceptable medium, at least 10% by weight of 8-hexadecene-1,16-dicarboxylic
10 acid,

(b) leaving the composition in contact with the skin for a time ranging from 5 minutes to 6 hours, and

(c) removing the composition by rinsing.

15 2. Process according to Claim 1, characterized in that the composition is left in contact with the skin, in step (b), for a time ranging from 5 minutes to 30 minutes.

20 3. Process according to Claim 1 or 2, characterized in that it is intended for attenuating wrinkles and fine lines and/or pigmentary marks and/or scars.

25 4. Process according to Claim 3, characterized in that the said scars are acne or chickenpox marks.

5. Process according to any one of Claims 1 to 4, characterized in that it is performed on individuals with acne and/or wrinkles and/or scars and/or
30 pigmentation defects.

6. Process according to any one of Claims 1 to 5, characterized in that the amount of 8-hexadecene-1,16-dicarboxylic acid represents from 10% to 50% of the
35 total weight of the composition.

7. Process according to Claim 6, characterized in that the amount of 8-hexadecene-1,16-dicarboxylic acid represents from 15% to 35% of the total weight of the

composition.

a)

8. Process according to any one of Claims 1 to 7, characterized in that the composition comprises, in a physiologically acceptable medium suitable for topical application to the skin: (a) from 10% to 50% by weight of 8-hexadecene-1,16-dicarboxylic acid and (b) from 0.1% to 15% by weight of at least one β -hydroxy acid, relative to the total weight of the composition.

10

9. Process according to Claim 8, characterized in that the said β -hydroxy acid is chosen from salicylic acid and derivatives thereof, or a salt of such a derivative.

15

10. Process according to Claim 9, characterized in that the said salicylic acid derivative is 5-n-octanoyl-salicylic acid.

20

11. Process according to any one of Claims 8 to 10, characterized in that the amount of β -hydroxy acid represents from 0.2% to 10% relative to the total weight of the composition.